Cardiff Oncology, Inc.
CRDF
$2.13
$0.094.41%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 19.26% | -3.79% | -13.97% | 0.57% | -0.65% |
| Total Depreciation and Amortization | -2.18% | 0.44% | 137.50% | -59.32% | -1.67% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -18.09% | 12.54% | 17.40% | -4.56% | 4.18% |
| Change in Net Operating Assets | -123.28% | 590.69% | -315.87% | 464.18% | -94.67% |
| Cash from Operations | -30.09% | 34.91% | -24.61% | 1.81% | -13.28% |
| Capital Expenditure | 30.77% | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 305.33% | 66.01% | -423.30% | 147.82% | -167.31% |
| Cash from Investing | 303.89% | 65.83% | -423.30% | 147.82% | -167.31% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -100.00% | -99.99% | 494.96% | 260.88% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -100.00% | -99.99% | 494.96% | 260.88% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 95.12% | 51.38% | -171.23% | 408.37% | -282.13% |